News & Updates

Adjuvant chemoradiotherapy (CRT) improves both 10-year overall survival (OS) and recurrence-free survival (RFS) in women with high-risk endometrial cancer vs pelvic radiotherapy alone, with the most clinically relevant benefit observed in p53 abnormal cancers, according to the 10-year analysis of the phase III PORTEC-3 trial.

First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.

Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).

A study from Italy suggests that the consumption of poultry – which includes all forms of chicken, turkey, duck, geese, guineas, quail, and pheasant as per the Dietary Guidelines for Americans 2020–2025 – ups the risk of death from gastrointestinal (GI) cancers, especially in men.

Pain and quality of life (QoL) outcomes from the phase III PANOVA-3 trial reinforce the role of tumour treating fields (TTFields) therapy when added to a chemotherapeutic regimen consisting of gemcitabine/nab-paclitaxel (GnP) for the treatment of individuals with locally advanced pancreatic adenocarcinoma.